Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Goethals, Olivia; Vos, Ann; Van Ginderen, Marcia; Geluykens, Peggy; Smits, Veerle; Schols, Dominique; Hertogs, Kurt; Clayton, Reginald

Goethals, Olivia; Vos, Ann; Van Ginderen, Marcia; Geluykens, Peggy; Smits, Veerle; Schols, Dominique; Hertogs, Kurt; Clayton, Reginald.

Affiliation

Goethals O; Tibotec Virco Virology BVBA, Gen De Wittelaan L 11B 3, 2800 Mechelen, Belgium.

Virology ; 402(2): 338-46, 2010 Jul 05.

Article in En | MEDLINE | ID: mdl-20421122

Subject(s)

Anti-HIV Agents/pharmacology; Drug Resistance, Viral; HIV Integrase Inhibitors/pharmacology; HIV Integrase/genetics; HIV-1/drug effects; Mutation, Missense; Pyrrolidinones/pharmacology; Amino Acid Substitution/genetics; DNA Mutational Analysis; HIV Integrase/chemistry; HIV-1/genetics; Humans; Models, Molecular; Protein Structure, Tertiary; Raltegravir Potassium

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrrolidinones / HIV-1 / HIV Integrase Inhibitors / HIV Integrase / Anti-HIV Agents / Mutation, Missense / Drug Resistance, Viral Limits: Humans Language: En Journal: Virology Year: 2010 Type: Article Affiliation country: Belgium

Fulltext

XML

PubMed Links

Search on Google